Partners in innovation
We interact with hundreds of companies in our labs – all accelerating toward proof of concept. We know these entrepreneurs; we’re all in it together.
The power of our community
We provide our resident companies with critical resources, help develop partnerships, and often make introductions to key corporate sponsors. It’s a founder-friendly approach that sets BioInnovation apart.
BioLabs San Diego
Avexegen Therapeutics is developing a novel approach to treating gastrointestinal disease which reduces inflammation and heals damaged tissue.
BioLabs North Carolina
Cereius Therapeutics is developing targeted radionuclides for treatment of brain metastases.
GraphWear is developing ultra-high sensitivity devices for monitoring blood glucose without the use of needles.
Mitokinin is developing therapeutics that selectively increase the activity of endogenous repair mechanisms for the treatment of neurodegenerative diseases like Parkinson’s disease.
Nocion Therapeutics is developing small molecule drugs that selectively silence nociceptors for treatment of cough, itch, and pain.
Pandion is developing bispecific antibody therapeutics for localized immunomodulation in autoimmune and inflammatory disease.
PanTher Therapeutics is developing a device for local delivery of chemotherapy to solid tumors. This approach reduces the toxicity associated with traditional systemic chemotherapy.
Photoswitch Biosciences is developing a high-throughput tool to screen ion channel activity of therapeutics for preclinical cardiotoxicity testing.
QurAlis is developing therapeutics for treatment of amyotrophic lateral sclerosis (ALS).
Sentien Biotechnologies is a clinical stage company which has developed an extracorporeal device to harness the therapeutic potential of mesenchymal stem cells without the difficulties of engraftment.
BioLabs San Diego
Shape Therapeutics is developing a novel gene correction platform which bypasses the limitations of CRISPR.
Totient is leveraging big data to develop novel therapeutics for oncology applications based on patient outcomes.
Vaxess Technologies is developing microneedle patch technology for sustained dermal vaccine delivery.